Enoblituzumab Plus MGA012 in Squamous Cell Carcinoma of the Head and Neck
Conditions: Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck Interventions: Biological: pembrolizumab; Biological: enoblituzumab; Biological: MGA012; Drug: Chemotherapeutic Combinations Sponsor: MacroGenics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | Research | Skin Cancer | Squamous Cell Carcinoma